Using genetic engineering in plants to create biopharmed drugs holds all sorts of promise for treating diseases, as the recent case of a drug which appears to have cured two Ebola patients has shown, but regulators may be holding this field back, argues Henry Miller in a Wall Street Journal op-ed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.